Physician profile
Peter Paul Rullan
NPI 1114963170
$8,693.73
in general payments reported to CMS, 2019-2025
29 companies · $1,821 in 2025
The $1,821 reported for 2025 was more than what 76% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $1,565 · 2021: $264 · 2022: $1,071 · 2023: $1,188 · 2024: $1,618 · 2025: $1,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,627.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,255.70 | 2019-2022 | |
| Abbvie INC. | $1,282.14 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Genzyme Corporation | $729.75 | 2022-2025 | |
| Galderma Laboratories, L.P. | $574.87 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Merz North America, INC. | $522.98 | 2020-2022 | |
| Pfizer INC. | $368.33 | 2019-2025 | |
| Janssen Biotech, INC. | $320.10 | 2021-2025 | Tremfya |
| Ucb, INC. | $284.44 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $252.44 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $251.95 | 2019-2025 | Ilumya |
| Leo Pharma INC. | $250.45 | 2023-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $250.35 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $229.60 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $209.31 | 2023-2025 | Zoryve |
| Amgen INC. | $143.94 | 2019-2025 | Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $138.91 | 2023-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.11 | 2024-2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $100.44 | 2024 | Sotyktu |
| Dermavant Sciences, INC. | $92.41 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $55.25 | 2019-2020 | |
| Almirall LLC | $51.27 | 2019 | |
| Biofrontera INC. | $48.46 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Mimedx Group, INC. | $41.22 | 2024 | |
| Organon LLC | $38.96 | 2025 | Vtama |
| Journey Medical Corporation | $23.87 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.38 | 2020 | |
| Botanix Sb INC | $19.25 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $16.11 | 2024 | Daxxify |
| Sensus Healthcare, INC. | $10.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rullan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.